000566 Hainan HaiyaoWatchlist
About Hainan Haiyao Company
The company was approved by the Hainan Provincial Joint Stock Exchange Pilot Leading Group (1992) in document No. 10 . It was jointly initiated and established by the Haikou State-owned Assets Administration Bureau, the Hainan Trust and Investment Company of the Industrial and Commercial Bank of China, Hainan Trust and Investment Company, the Hainan Branch of the Bank of Communications, and Huitong International Trust and Investment Company. It was registered with the Hainan Administration for Industry and Commerce on December 30, 1992, and is headquartered in Haikou City, Hainan Province. The company currently holds a business license with a unified social credit code of 91460000201289453D, a registered capital of 1,335,979,264.00 yuan, and a total of 1,335,979,264 shares (face value of 1 yuan per share). The company's shares were listed and traded on the Shenzhen Stock Exchange in May 1994. The company's layout revolves around big health, covering the fields of intermediates, APIs, chemical preparations, medical devices, modern traditional Chinese medicine, biomedicine and medical services. Currently, it mainly focuses on R&D, production and sales of pharmaceuticals and medical devices. The company's main products throughout the year include six major series, namely antibiotic series, gastrointestinal medication series, antitumor drug series, cochlear implant series, and formulation A set of APIs and intermediates series and other products. Corporate honors: High-tech enterprises in Hainan Province; Vice Chairman's unit; Top 50 industrial enterprises in Hainan; Top 10 tax-paying enterprises, etc.